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Abstract
Background: Previous studies in long-term care (LTC) have demonstrated that warfarin management is suboptimal 
with preventable adverse events often occurring as a result of poor International Normalized Ratio (INR) control. To 
assist LTC teams with the challenge of maintaining residents on warfarin in the therapeutic range (INR of 2.0 to 3.0), we 
developed an electronic decision support system that was based on a validated algorithm for warfarin dosing. We 
evaluated the MEDeINR system in a pre-post implementation design by examining the impact on INR control, testing 
frequency, and experiences of staff in using the system.
Methods: For this feasibility study, we piloted the MEDeINR system in six LTC homes in Ontario, Canada. All128 
residents (without a prosthetic valve) who were taking warfarin were included. Three-months of INR data prior to 
MEDeINR was collected via a retrospective chart audit, and three-months of INR data after implementation of MEDeINR 
was captured in the central computer database. The primary outcomes compared in a pre-post design were time in 
therapeutic range (TTR) and time in sub/supratherapeutic ranges based on all INR measures for every resident on 
warfarin. Secondary measures included the number of monthly INR tests/resident and survey/focus-group feedback 
from the LTC teams.
Results: LTC homes in our study had TTR's that were higher than past reports prior to the intervention. Overall, the TTR 
increased during the MEDeINR phase (65 to 69%), but was only significantly increased for one home (62% to 71%, p < 
0.05). The percentage of time in supratherapeutic decreased from 14% to 11%, p = 0.08); there was little change for the 
subtherapeutic range (21% to 20%, p = 0.66). Overall, the average number of INR tests/30 days decreased from 4.2 to 
3.1 (p < 0.0001) per resident after implementation of MEDeINR. Feedback received from LTC clinicians and staff was that 
the program decreased the work-load, improved confidence in management and decisions, and was generally easy to 
use.
Conclusion: Although LTC homes in our sample had TTR's that were relatively high prior to the intervention, the 
MEDeINR program represented a useful tool to promote optimal TTR, decrease INR venipunctures, streamline 
processes, and increase nurse and physician confidence around warfarin management. We have demonstrated that 
MEDeINR was a practical, usable clinical information system that can be incorporated into the LTC environment.
Background
Warfarin therapy is indicated to reduce the risk of arterial
and venous thromboembolism [1] and is a common treat-
ment for many elderly patients [2-4]. When warfarin is
properly monitored and maintained within a narrowly
defined range, it is a safe and highly effective therapy. For
most warfarin indications (atrial fibrillation, deep venous
thrombosis, and pulmonary embolism) the optimal ther-
apeutic range, is an International Normalized Ratio (INR)
of 2.0 - 3.0 [1]. The consequences of poor INR control are
serious and include increased risk for death, myocardial
infarction, major bleeding, and stroke [5].
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The frail elderly residing in long-term care (LTC) have
several prescribing challenges [6-8] with additional barri-
ers specific to anticoagulation such as higher risk for
recurrent thromboembolism and major bleeding, polyp-
harmacy, and increased risk of falls [4,9]. Indeed, antico-
agulants are one of the most common causes of drug-
related adverse events in LTC; the majority of events are
attributable to poor anticoagulant control leading to
excessive INR's [10-12]. In a study of 25 LTC homes [13],
57% of serious or fatal and 24% of minor warfarin-related
adverse events were considered preventable; nearly all of
the preventable adverse events occurred in the prescrib-
ing and monitoring stages of warfarin therapy. Improved
anticoagulation care in the elderly has become a priority
for several organizations including the Joint Safety Com-
mission [14].
Despite proven benefits and indication for use regard-
less of age [1], warfarin is commonly under-prescribed in
the elderly [2,15,16]. Even when prescribed, many LTC
physicians are uncertain about the appropriate intensity
of warfarin and in some cases aim for a subtherapeutic
target [17,18]. In an audit we conducted in LTC, a large
proportion of the time (27.7%) was spent in the INR
range of 1.6-1.9 [19]. A recent meta-analysis reported
that patients were safer with a ratio slightly above rather
than below the therapeutic range when both hemorrhagic
and thromboembolic events were considered, and the
authors promote the importance of using computer-
based algorithms to avoid systemic under-anticoagula-
tion [18,17]. In the community setting, anticoagulation
c l i n i cs  a r e  o ft e n  u s ed  t o  m a n a g e  pa t i e n ts  o n  wa rfa ri n ,
however in the LTC setting other options must be
explored.
Utilizing a 'knowledge to action' framework [20,21],
whereby "the process of translating knowledge to action
is an iterative, dynamic and complex process", this project
was designed to address 3 objectives: 1) the application of
evidence to improve warfarin care in LTC settings 2)
develop an electronic decision support system that facili-
tates the prescribing and monitoring stages of warfarin
care in LTC and 3) provide training and support to pro-
mote uptake of the tools and overcome implementation
barriers. Thus we developed the MEDeINR evidence-
based computer system for assisting LTC teams with war-
farin management and conducted a feasibility study to
examine its implementation in six pilot LTC homes. The
primary outcome we compared in a pre-post implemen-
tation design was the percentage of time in the therapeutic
range (TTR), subtherapeutic range, and supratherapeutic
range. Our secondary objectives were to examine
whether the number of monthly INR tests per resident
changed after implementing the MEDeINR program and
to obtain feed-back from LTC staff on using the
MEDeINR system.
Methods
This project involved a partnership between clinician
researchers and a large pharmacy provider (Medical
Pharmacies Group Inc.) that provides complete phar-
macy care (medication packaging and distribution, clini-
cal support and consulting services) to over 35,000
residents in LTC homes across Ontario, Canada. This was
the final phase of a larger project on improving prescrib-
ing in LTC. A previous focus group conducted with LTC
family physicians identified that warfarin prescribing was
one of their key areas of concern. Previous activities
included drug utilization reviews, an audit of warfarin
prescribing and monitoring practices in our practice area
[19], multi-disciplinary education and training (physi-
cians, nursing, and pharmacy), and academic detailing by
senior consultant pharmacists and a geriatrician.
Description of LTC Homes and Study Cohort
Six LTC homes in the province of Ontario, Canada were
chosen to pilot this program. The total residents in all six
facilities was 1268 (Centre 1: n = 370; Centre 2: n = 184;
Centre 3: n = 64; Centre 4: n = 128, Centre 5: n = 234,
Centre 6: n = 288). All residents taking warfarin were
included in the study cohort, with the exception of resi-
dents who had a prosthetic valve. As this was a feasibility
study to determine how the system would function in
practice, the majority of homes chosen to participate
have been involved in past quality improvement studies,
or are centres for university residency trainees in primary
care. Many have physicians affiliated with an academic
health science centre and have access to specialists and
academics on a routine basis. Overall, there were 19 pre-
scribing physicians with the number per facility ranging
from 1 - 6 physicians.
Description of MEDeINR Decision Support System
MEDeINR (Figure 1) was designed as a web-based tool to
assist LTC staff and clinicians with the day to day man-
agement of warfarin. It was available on-line, 24 hours a
day. LTC staff, clinicians, and pharmacists were consulted
in the development phase as to specific needs and poten-
tial barriers and facilitators.
The first step of developing MEDeINR was to modify
an algorithm for warfarin dosing validated in acute care/
community settings [22] for the elderly patient. Previous
studies indicate that warfarin dose requirements decrease
with older age [23]. The modified algorithm was devel-
oped by an expert in anticoagulation, a geriatrician, and
academic and consultant pharmacists. In the next step,
computer programmers developed the algorithm into the
MEDeINR computer tool which was extensively validated
for accuracy.
The MEDeINR system worked in the following way: An
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(nurse/clinician/other staff) then logs on to MEDeINR
and enters the following data elements: physician name,
resident's name, indication for warfarin, current INR
value, daily "administered" dose for the 7 days prior to the
INR value, current antibiotic information (if applicable).
Then, based on the inputs, MEDeINR recommends an
overall weekly dose and a specific daily dose is also pro-
vided (in order to reduce chance of human error in trans-
lating weekly doses to daily doses). For this study, nursing
staff printed the MEDeINR recommendation, contacted
the physician (via phone or fax), faxed MEDeINR recom-
mendation forms to the pharmacy and also placed the
original on the resident's chart. Ultimately any dosing/
testing changes were at the discretion of the physician,
and the physician could choose not to use the dose sug-
gested by the MEDeINR algorithm and provide an alter-
native order that was documented by hand in the
'Specialized Dosing' section. Physicians could request
Figure 1 The MEDeINR computer toolPapaioannou et al. BMC Geriatrics 2010, 10:38
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access to the on-line tool if they wished to check
MEDeINR recommendations themselves.
Training and Knowledge Dissemination
Selected nurses in the participating LTC homes were cho-
sen to carry out all warfarin monitoring and MEDeINR
activities. These nurses were provided with a "user's man-
ual" and in-person training by consultant pharmacists.
Physicians were consented and also received training.
Data Collection and Evaluation
Prior to beginning the study, approval was obtained from
the family physicians, Medical Director, Administrator,
and Director of Care at each LTC home. Ethics approval
was received from the Research Ethics Board at McMas-
ter University. A pre-post implementation study design
was utilized to evaluate the MEDeINR system. The study
cohort (all patients taking warfarin and without a pros-
thetic valve) was identified via the central pharmacy data-
base just prior to implementing the MEDeINR system
(i.e., considered baseline). Three-months of pre-imple-
mentation data was collected via a retrospective chart
audit by consultant pharmacists and three-months of
prospective data was collected via the MEDeINR com-
puter system (i.e., post-implementation data). All INR
data collected via the computer system was also audited/
validated by consultant pharmacists via a comparison
with laboratory records. Data collected in pre and post-
phases included indication for warfarin, recommended
INR range, weekly warfarin doses, INR values, and antibi-
otic information. Further information including demo-
graphics, co-morbidities and concomitant drug
information were obtained from the central pharmacy
database. All residents must have been on warfarin in
both the pre and post data collection phases, however
some patients may have had fewer than 3-months of INR
data in either phase (e.g., if a resident had not been resid-
ing in the facility for the entire 3-months during the pre-
implementation period or died during the post-imple-
mentation phase).
To elicit feed-back about their experience with
MEDeINR, a brief on-line survey was sent to LTC staff
directly involved in the pilot project. The online survey
program SurveyMonkey [24] was used to design, collect
and store survey responses. The survey was distributed to
15 LTC staff who were directly involved in the MEDeINR
pilot within each home. The roles and numbers varied by
home, but generally 2-3 people were responsible for coor-
dinating MEDeINR (in most cases it was nurses, but
other relevant staff including the Director of care, consul-
t a n t  p h a rm a ci s t  w e r e  a ls o  s u rv ey ed  i n  c e rt a i n  h o m e s ) .
The survey was also sent to 6 physicians. The survey con-
tained 8 closed-ended questions, and 2 open-ended ques-
tions where perceptions and beliefs about the system
could be expanded upon. Participants were asked about
their confidence in using MEDeINR to monitor warfarin
and to rate the "user-friendliness" of the computer tool.
They were also surveyed about the perceived impact of
MEDeINR on INR testing, work-load, team-work, and
communication between LTC staff and physicians.
A focus group with three physicians, two nurses, and
one consultant pharmacist from two facilities was also
conducted to obtain further feed-back. There were two
main open-ended questions at the focus group: 1) what
aspects of MEDeINR could be improved or changed? 2)
what did you like about MEDeINR? A researcher familiar
with qualitative methodology led the focus group and
results were transcribed and summarized. Several of the
co-investigators were present at the focus group so they
could address questions and concerns and utilize the
knowledge to improve upon the MEDeINR program.
Statistical Analysis
We compared study outcomes between the pre and post
implementation periods using a 'within patient' compari-
son/paired analysis. All INR values for every resident on
warfarin were included, with the exception of residents
who had fewer than 2 INR values in either the pre or post
phase. Residents who died during the study period were
included as long as they had the minimum number of
INR values. Rosendaal's [25] method of linear interpola-
tion of INR was used to characterize each day of warfarin
therapy: INR values were assigned to each day between
INR measurements based on a postulated linear change.
Values were rounded to one decimal place. All analyses
were conducted overall and for each individual LTC
home. Paired t-tests (2-tailed) were utilized to compare
the percent of time spent in therapeutic, sub-therapeutic
and supratherapeutic range for the pre versus post-imple-
mentation periods. Therapeutic range was considered an
INR value between 2.0 and 3.0. In secondary analyses, a
paired t-test was used to examine pre/post differences in
the mean number of INR measures/30 days per resident.
Results
Our final cohort was 128 residents taking warfarin in six
LTC homes, representing 10% of all residents. The mean
age of residents taking warfarin was 85.9 [standard devia-
tion (SD) 8.0]; 25 percent were male. The primary indica-
tions for taking warfarin were: atrial fibrillation (74%),
deep venous thrombosis (20%), pulmonary embolism
(6%). Residents had several common co-morbidities
(Table 1).
INR
A total of 1308 INR values were recorded during the pre-
data phase over 9495 resident days. A total of 1213 INR
values were recorded over 11557 resident days during thePapaioannou et al. BMC Geriatrics 2010, 10:38
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MEDeINR phase. The mean number of days of INR mon-
itoring per patient (difference between first and last INR
dates) was 74 days (range 17-101) in the pre-phase and 90
days (range 27-131) in the post-phase. Figures 2 through
4 compare the percentage of time spent in a) therapeutic
range b) below range (subtherapeutic) and c) above range
(supratherapeutic) for the pre and post implementation
periods. Overall, the TTR increased during the
MEDeINR phase (65 to 69%, p = 0.14), but was only sig-
nificantly increased for Centre 1. There was little change
in the pre versus post periods for the subtherapeutic
range, with the exception of Centre 2 (Figure 3). The per-
centage of time spent in supratherapeutic range also
decreased from 14% to 11% (p = 0.08) overall, and for
Centres 1,3,5 and 6 (Figure 4) but was not significant.
Testing Frequency
Figure 5 displays the INR testing frequency for all resi-
dents in our study (overall and by home) between the pre
and post implementation periods. The average number of
INR tests/30 days per resident was lower in the
MEDeINR period overall (4.2 to 3.1, p < 0.001) and for
Centre 3 (4.0 to 2.3, p < 0.05), Centre 5 (5.3 to 3.2, p <
0.001) and Centre 6 (5.4 to 3.0, p < 0.001).
Adverse Events
No major adverse events requiring hospitalization were
reported; minor or those not requiring hospitalization
were not recorded.
Survey and Focus Group
Twelve participants (4 physicians, 8 nursing/administra-
tion/pharmacy staff) responded to the survey. After
learning how to use MEDeINR, 100% of respondents
reported that MEDeINR was easy/very easy to use. Com-
pared to previous warfarin monitoring, 75% believed it
decreased workload, 17% perceived no change in work-
load, and 1 respondent (8%) perceived an increase in
workload. Compared to previous warfarin monitoring,
80% reported increased confidence using MEDeINR; 20%
reported the same level of confidence. When respondents
were asked about communication between LTC staff and
physicians regarding warfarin management, 92% of
respondents felt communication was better (more timely,
e t c . )  w i t h  M E D e I N R ;  8 %  r e p o r t e d  n o  c h a n g e .  W i t h
regards to team-work related to warfarin management,
67% reported that MEDeINR improved team-work and
33% reported no change from the previous system. For
respondents from facilities that implemented an INR
monitoring/tracking form (n = 9), 67% believed it
improved/streamlined INR collection and 33% reported
no change (similar to old system). Respondents were also
asked about their perceptions of MEDeINR testing fre-
quency: 56% reported a decrease in INR testing, 33% felt
it increased INR testing, and 11% reported no change. In
focus group feedback, the overall consensus was that the
program decreased the work-load, improved confidence
in management and decisions, and was generally easy to
use. The physicians felt there was a decrease in the phone
calls/contacting by staff and fewer INR problems to deal
with. Physicians also believed that it decreased some of
the anxiety regarding warfarin by nursing staff. Partici-
pants believed that more training was needed due to the
higher turnover in staffing and to ensure that on-call phy-
sicians are aware of the program. To introduce new staff
to the program, it was suggested that a video be made for
training purposes and that 1 or 2 nursing staff be desig-
nated to lead this training with new staff. It was also re-
iterated that attaching a tracking sheet with a patient's
INR history is an important part of the process (in some
facilities this was already implemented).
Discussion
In this feasibility study, we applied evidence into practice
by developing and piloting an electronic decision support
system (MEDeINR) for managing warfarin in the LTC
environment. To our knowledge, this electronic warfarin
Table 1: Baseline patient characteristics, n = 128
Characteristic No. (percent) or Mean (SD)
Age 85.9 (8.0)
Male 32 (25)
Primary Indication for Warfarin
Atrial Fibrillation 95 (74)
Deep Venous Thrombosis 16 (20)
Pulmonary Embolism 7 (6)
Co-morbidities
Hypertension 61 (48)
Coronary Artery Disease 45 (35)
Cerebrovascular Accident 45 (35)
Congestive Heart Disease 21 (16)
Diabetes 21 (16)
COPD 14 (11)
Cardiac Arrythmias 12 (9)
Malignancy 12 (9)
Peripheral Vascular Disease 8 (6)
Other Heart Condition (Murmur, 
Valvular, Congenital)
6 (5)
Amiodarone use 7 (6)
No. = Number; SD = standard deviationPapaioannou et al. BMC Geriatrics 2010, 10:38
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system is the first of its kind employed in LTC homes.
Warfarin monitoring is an area of concern for may LTC
clinicians and staff, and we were able to successfully
implement the MEDeINR program into daily practice in
our six pilot homes.
When we examined the percentage of time in therapeu-
tic, subtherapeutic and supratherapeutic range in the pre
versus post implementation periods, the overall TTR (all
homes combined) after implementing MEDeINR
increased non-significantly from 65% to 69%, the per-
centage of time in supratherapeutic range decreased non-
significantly from 14% to 11%, and there was little change
for the subtherapeutic range.
For this feasibility study, LTC homes were selected as
they had either pharmacists or physicians who were
involved in quality improvement initiatives and may be
"early adopters" of evidence [26,27]. Thus, it is not sur-
prising that before we implemented MEDeINR, the
homes in our study had baseline TTR's much higher than
previous studies in LTC which report TTR's of 37-51%
[2,10,13,16]. All but one home in our study had a baseline
TTR above 60% (considered moderately well-controlled
[5]). The baseline TTR's were also higher than a previous
audit we conducted in our own practice setting, which
found an overall TTR in five LTC homes of 54% [19].
Since developing MEDeINR was the final phase of a
larger initiative on improving drug prescribing in LTC,
some of our pilot homes may have directly or indirectly
been influenced by our previous activities (e.g. in-ser-
vices, academic detailing, and in some cases audit and
feedback on prescribing practices which may have
included warfarin). Thus, although we did not see a sig-
nificant increase, our pilot homes either improved or
maintained good TTR's. We hypothesize that homes with
poorer warfarin control would see greater gains with
MEDeINR.
One of our other objectives was to examine how
MEDeINR impacted on the frequency of INR testing. An
important finding was that the number of INR tests
ordered during the MEDeINR period was considerably
reduced while at the same time either maintaining or
improving TTR. In the homes with the greatest testing
reduction (Centres 5 and 6), the number of INR's per 30
days decreased from approximately 5 to 3 in pre versus
post-implementation periods. This has implications in
terms of quality of life for elderly LTC residents (fewer
venipunctures), a decrease in staff time for both labora-
tory and LTC workers, and a decrease in costs associated
with testing.
Given that this was a feasibility study to determine
whether MEDeINR could be successfully integrated into
daily practice, we obtained feedback from the LTC teams
Figure 2 Percent of time spent in therapeutic range
71
66
75
77
63
67
69
62
58
76
74
66
66
65
0 1 02 03 04 05 06 07 08 09 0
Center 1
Center 2
Center 3
Center 4
Center 5
Center 6
Overall
Percent of Time
Pre
Post (MEDeINR)
* *p<0.05Papaioannou et al. BMC Geriatrics 2010, 10:38
http://www.biomedcentral.com/1471-2318/10/38
Page 7 of 10
regarding their experiences with MEDeINR. The results
of our survey indicate that the majority of respondents
believed MEDeINR was easy to use, decreased workload,
increased confidence in monitoring warfarin, improved
communication between LTC staff and physicians, and
improved team-work related to warfarin management.
Furthermore, the physicians in our focus group felt there
was a decrease in the phone calls/contacting by staff,
fewer INR problems to deal with, and a decrease in the
anxiety regarding warfarin monitoring by nursing staff.
Since LTC physicians must rely in part on the LTC team
to provide appropriate warfarin monitoring, the benefit
of MEDeINR is that it provided support for the entire
LTC team. Interestingly, a prior survey of LTC physicians
indicated that although the majority agreed an anticoagu-
lation service would be beneficial for improving TTR's
and reducing workload, approximately half believed an
anticoagulation service would intrude on physician deci-
sion-making and they would not utilize one for LTC resi-
dents [28]. From our feedback, it appeared MEDeINR
was a good balance between decision making and conve-
nience that LTC physicians may desire.
One of our primary limitations was that we may not
have had adequate sample size, particularly in the smaller
homes, to see potentially significant changes in TTR and
INR testing frequency. Another limitation was the lack of
a run-in period after implementation of MEDeINR (to
work out any initial bugs), so it is possible our estimates
of TTR during the MEDeINR phase are underestimated.
Implementation of the program was not without its
challenges. As issues arise, support and infrastructure is
needed to deal with questions and concerns and ongoing
education is needed to ensure proper use and when staff
turn-over occurs. This process was led by the pharma-
cists with support from the investigative team. Although
the overall response to the program was positive, in one
home, it was noted by the Director of Care that the physi-
cians may not have been fully aware of the program and
as a result were not interested in its continued use. One of
the suggestions in feedback received from staff was that a
video be made for training purposes. Confusing terms,
implementation and process issues have been discussed
and improved upon in keeping with the idea that translat-
ing knowledge to action is an "iterative, dynamic and
complex process" [20].
Despite some of the challenges and barriers to warfarin
management in the LTC environment, there are several
facilitators that actually make the LTC environment an
ideal setting to manage warfarin (versus patients in the
community or acute settings). For example, the super-
Figure 3 Percent of time spent below therapeutic range
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Figure 4 Percent of time spent above therapeutic range
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vised medication administration and the availability of
routine laboratory draws on-site are both added benefits.
Since an anticoagulation service may not be feasible in
the LTC setting, MEDeINR builds on the team-based
approach to care and the closely supervised environment
of LTC homes. Although we did not formally examine the
impacts on work-load and costs, the perception was that
MEDeINR had a beneficial effect on these and we know
quantitatively that residents had fewer INR-related veni-
punctures.
The uptake of MEDeINR system in our pilot nursing
homes demonstrates that it was a practical, usable clinical
information system that can be incorporated into the
LTC environment. The final step of the "knowledge to
action" framework is ensuring sustained use of knowl-
edge [20,21]. At every step, the end-users of the knowl-
edge - the LTC teams - were included to ensure that
MEDeINR met their needs and necessary changes were
made to improve upon the system. Since this was a coop-
erative approach, integrating both academia and industry,
we believe that MEDeINR can be sustained. Our partner
pharmacy provider has already implemented MEDeINR
in 30 homes. Our next steps will be to evaluate MEDeINR
at a wider level, including homes that have not been influ-
enced by other prescribing initiatives and over a longer
time period. With a larger sample size and duration, we
will also examine whether MEDeINR has any effect on
reducing serious hemorrhagic and thromboembolic
events.
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